Midostaurin 13C6
| Product Name | Midostaurin 13C6 |
|---|---|
| Alternate Names | Midostaurin Stable Isotopes, Stable Isotopes of Midostaurin |
| CAT No. | CS-T-93582 |
| CAS No. | 120685-11-2 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 576.59 g/mol |
| Mol. For. | C₂₉¹³C₆H₃₀N₄O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Midostaurin |
| Smileys | O=C1NCC(C1=C23)=C4C(N5C6=C4C=CC=C6)=C2N([C@H]7C[C@@H](N(C([13C]8=[13CH][13CH]=[13CH][13CH]=[13CH]8)=O)C)[C@@H](OC)[C@]5(C)O7)C9=C3C=CC=C9 |
| Canonical Smiles | CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC |
| InchIKey | BMGQWWVMWDBQGC-IIFHNQTCSA-N |
| Inchl | InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1 |
| IUPAC | N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Midostaurin 13C6 is a highly potent and selective inhibitor of protein kinases, primarily used in the treatment of acute myeloid leukemia (AML) and advanced systemic mastocytosis. The drug is classified as a small molecule kinase inhibitor and works by blocking the activity of certain enzymes that are involved in the growth and proliferation of cancer cells.
Midostaurin 13C6 is administered orally and is rapidly absorbed by the body. The drug is metabolized in the liver and excreted primarily through the feces. The recommended dosage of Midostaurin 13C6 varies depending on the type and severity of the cancer being treated.
Chemically, Midostaurin 13C6 is a derivative of staurosporine and belongs to the class of indolocarbazole compounds. It is a white to off-white crystalline powder with a molecular weight of 651.77 g/mol. The compound contains 6 carbon-13 isotopes, which are stable and non-radioactive.
Midostaurin 13C6 has shown promising results in clinical trials, demonstrating significant improvements in survival rates and overall response rates in patients with AML and systemic mastocytosis. However, the drug is not without its side effects, which can include nausea, vomiting, diarrhea, fatigue, and low blood cell counts.
In conclusion, Midostaurin 13C6 is a potent and promising drug in the treatment of certain types of cancer. Its unique chemical structure and mechanism of action make it a valuable addition to the arsenal of drugs used in cancer therapy.
Get an Instant Quote
Related Compounds
O-Desmethyl Midostaurin-13C6 | Midostaurin D5 | Midostaurin metabolite-13C6 (CGP52421) | O-Desmethyl Midostaurin D5 |